Anixa Biosciences, a biotechnology company focused on the treatment and prevention of cancer, has announced that a patient in its ongoing phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.
This represents the first such response in Anixa’s CAR-T cell therapy trial. Correlative studies evaluating presence and durability of CAR positive cells are ongoing.
The patient was treated in the fifth dose cohort and received a dose of 1×10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, representing the highest dose level evaluated to date in the study. To date, no dose-limiting toxicities have been observed in any patients.
The phase 1 study is evaluating liraltagene autoleucel, or lira-cel, Anixa’s novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on ovarian cancer cells but has limited expression in healthy tissues.
The trial is designed to assess safety, tolerability, and preliminary signs of efficacy across escalating dose levels. The study is being conducted at Moffitt Cancer Center.
